A Phase II Study of Single Agent Intravenous (IV) in Patients With Poor Prognostic Recurrent and/or Metastatic Thyroid Cancer After RAI Therapy.
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2017
At a glance
- Drugs Aflibercept (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 02 Jun 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 12 Jun 2013 Planned end date changed from 1 May 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.